Anti-HA Antibody Market

Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called antigens ). The technology behind the generation of monoclonal antibodies was discovered in 1972 by C sar Milstein and Georges K hler scientists at the Roche-funded Basel Institute for Immunology who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological research and built the basis for the use of therapeutic antibodies in medicine and for the entire biotechnology industry.

In Vitro Diagnostics (IVD) are tests used to detect disease, infections and other medical conditions. The growing need of IVD testing arises due to increasing incidences of chronic and infectious diseases and growing geriatric population prone to immunological disorders. Moreover, increased application of personalized medicines and widespread knowledge of rare diseases are boosting the growth of IVD market. In the recent years, antibody used for IVD industry developed rapidly in China

Anti-HA Antibody Market contains market size and forecasts of Anti-HA Antibody in global, including the following market information:

• Global Anti-HA Antibody Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Anti-HA Antibody Market Sales, 2017-2022, 2023-2028, (K Doses)
• Global top five Anti-HA Antibody companies in 2021 (%)

The global Anti-HA Antibody market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

IgM Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Anti-HA Antibody include Roche, Johnson & Johnson, Merck, Novartis, AbbVie, Amgen, Pfizer, Bayer and Lilly, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-HA Antibody manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Anti-HA Antibody Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Anti-HA Antibody Market Segment Percentages, by Type, 2021 (%)

• IgM
• IgG
• IgA
• Other

Global Anti-HA Antibody Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Anti-HA Antibody Market Segment Percentages, by Application, 2021 (%)

• Therapeutic
• Research
• Diagnostic

Global Anti-HA Antibody Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Anti-HA Antibody Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Anti-HA Antibody revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Anti-HA Antibody revenues share in global market, 2021 (%)
• Key companies Anti-HA Antibody sales in global market, 2017-2022 (Estimated), (K Doses)
• Key companies Anti-HA Antibody sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche
• Johnson & Johnson
• Merck
• Novartis
• AbbVie
• Amgen
• Pfizer
• Bayer
• Lilly
• Bristol-Myers Squibb
• GlaxoSmithKline
• Biogen
• AstraZeneca
• Sanofi
• Alexion Pharmaceuticals
• Seattle Genetics